30 results about "Sedative agent" patented technology

The present invention generally relates to pharmaceutical compositions comprising a dopamine agonist and sedative agent. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine. In a preferred embodiment, the sedative agent is optically pure (S)-zopiclone or optically pure (S)—N-desmethylzopiclone. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine; and the sedative agent is optically pure (S)-zopiclone or optically pure (S)—N-desmethylzopiclone. The pharmaceutical compositions of the invention are useful in the treatment of restless-leg syndrome and periodic-limb-movement disorder, as well as various sleep disorders. In addition, the present invention relates to a method of treating a patient suffering from restless-leg syndrome, periodic-limb-movement disorder, a sleep abnormality, or insomnia, comprising coadministering a therapeutically effective amount of a dopamine agonist and a therapeutically effective amount of a sedative agent. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine. In a preferred embodiment, the sedative agent is optically pure (S)-zopiclone or optically pure (S)—N-desmethylzopiclone. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine; and the sedative agent is optically pure (S)-zopiclone or optically pure (S)—N-desmethylzopiclone.

Arylalkyl ketone piperazine derivatives of the formula:and pharmaceutical compositions comprising the same. Also disclosed are methods for using the compounds as analgesic and sedative agents. The compounds of the present invention have good analgesic and sedative activities but few side effects.

A method for treatment of severe diffuse acute respiratory distress syndrome in an intubated-ventilated patient which includes sedating said patient with at least one alpha-2 agonist, maintaining spontaneous ventilation and applying pressure support ventilation of at least 5-10 cmH2O combined to a high positive end expiratory pressure (PEEP) of 10-24 cmH2O. A pharmaceutical composition containing at least one alpha-2 agonist suitable for treatment of ARDS in combination with, if appropriate, at least one sedative agent which does not depress ventilatory drive is also disclosed.

An object of the present invention is to provide a novel sleep-improving agent and sedative agent. The above object is achieved by providing a sleep-improving agent and a sedative agent containing, as an active ingredient, oxypinnatanine or its derivative represented by the following chemical formula (I).

The present invention relates to stable premix formulations for parenteral use and packaging for such formulations. The present invention relates to use of a single layer or multilayer film bags comprising polypropylene for packing premixed injectable formulations which remain stable during the storage period.The present invention relates to use of a single layer or multilayer film bags comprising polypropylene for packing dexmedetomidine premixed formulations. Such stable premixed formulations packed into a single layer or multilayer film bags comprising polypropylene are highly advantageous since they are ready-to-use, for example, in perioperative care of a subject in need thereof for sedation.

The invention provides an ibuprofen-containing pharmaceutical composition, which also comprises arginine and preferably propylene glycol. The invention also provides a preparation method and an application of the pharmaceutical composition. The composition provided by the invention is mainly used to treat patients with pains from light to moderate degree, and can be also used as an auxiliary treatment drug of anesthetic sedative agents to alleviate pains from moderate to severe degree or febrile diseases emerged in patients.

The invention provides a method for synthesizing fospropofol sodium and an intermediate thereof, including intermediate B and intermediate C, and the application of fospropofol sodium prepared by the synthetic method in an anesthetic sedative for animals . The method for synthesizing fospropofol sodium provided by the invention avoids using the highly toxic reagent chlorobromomethane, and has high safety; the prepared fospropofol intermediate has mild reaction conditions, simple and convenient operation, and the mass yield: >97%, which is easy to use. Industrialized production, the propofol prodrug prepared by the fospropofol sodium synthesized by the synthetic method provided by the present invention can produce the same clinical effect as the commercially available propofol emulsion injection, and no fospropofol anesthesia occurs induced myocardial depressive response.

The present disclosure relates to an improved process for the preparation of isochroman structured alpha2A adrenoceptor agonist, namely 2-(5-methoxyisochroman-1-yl)-4,5-dihydro-1H-imidazole of formula (I) and a pharmaceutically acceptable salts thereof, such as 2-(5-methoxyisochroman-1-yl)-4,5-dihydro-1H-imidazole hydrogensulfate of formula (Ia), and to a novel intermediate compound used in the process, namely N-(2-aminoethyl)-5-methoxyisochroman-1-carboxamide monohydrate of formula (V). Alpha2A agonists are useful in the treatment of anxiety, and for use as a sedative or analgesic agent, and other diseases where alpha2A agonism is desired.

The present invention is related to a new series of chemical compounds, namely 3-benzyl-imidazolidine-2,4-dione substituted in the position 2 and / or 6 of benzyl ring by halogens as presented to the molecule named LPSF-PT-31, GIRSUPAN and its therapeutic use as drug with analgesic, sedative and adjuvant of anesthetics activities. The invention is also related to a process for production of said compounds as well as pharmaceutical compositions comprising them.

An external defibrillator system such as a WCD is also capable of providing transthoracic pacing and drug delivery (e.g., pain-reducing drugs and / or a sedatives) to a patient. The drug(s) may be included in the therapy electrode electrolyte and dispensed for defibrillation, cardioversion and / or pacing therapy. Alternatively, the drug(s) may be stored in a separate reservoir and dispensed during pacing therapy. The drug(s) may be dispensed to a patient after a successful defibrillation therapy. The pacing therapy may be delivered a set time-period after the drug(s) were dispensed. A relatively small electric current may be delivered to the area of the patient on which the drug(s) were dispensed to facilitate drug absorption.

A method, system and computer-readable medium are provided for determining compliance with patient care protocols, comprising an infusion pump providing infusion information pertaining to one or more drugs administered to a patient, the one or more drugs including sedatives and analgesics, and a processor communicably coupled to the infusion pump and configured to determine information regarding the one or more drugs being administered to the patient based on the infusion information by determining a baseline threshold for the one or more drugs being administered to the patient according to the actual dosage of the one or more drugs administered to the patient prior to a current time, determining a dosage amount of the one or more drugs currently being administered to the patient and comparing the dosage amount of the one or more drugs currently being administered to the baseline threshold to determine a deviation from the baseline threshold.